Rigel to Present at BIO CEO & Investor Conference

              Rigel to Present at BIO CEO & Investor Conference

PR Newswire

SOUTH SAN FRANCISCO, Calif., Feb. 7, 2013

SOUTH SAN FRANCISCO, Calif., Feb. 7, 2013 /PRNewswire/ -- Rigel
Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the
company's chairman and chief executive officer, is scheduled to present a
company overview at the 15^th Annual BIO CEO & Investor Conference in New York
City on Monday, February 11th at 10:00 a.m. ET.

To access the live webcast of the presentation or the subsequent archived
recording, log on to www.rigel.com. Please connect to Rigel's website several
minutes prior to the start of the live webcast to ensure adequate time for any
software download that may be necessary.

About Rigel (www.rigel.com)

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a clinical-stage drug
development company that discovers and develops novel, small-molecule drugs
for the treatment of inflammatory and autoimmune diseases, as well as muscle
disorders. Rigel's pioneering research focuses on intracellular signaling
pathways and related targets that are critical to disease mechanisms. Rigel's
productivity has resulted in strategic collaborations with large
pharmaceutical partners to develop and market its product candidates. Current
product development programs include fostamatinib, an oral SYK inhibitor that
is in Phase 3 clinical trials for rheumatoid arthritis with its partner
AstraZeneca; R343, an inhaled SYK inhibitor for asthma and R333, a topical
JAK/SYK inhibitor for discoid lupus – both of which have commenced Phase 2
clinical trials; and, R348, a topical JAK/SYK inhibitor in a Phase 1 clinical
trial for the treatment of chronic dry eye.

Contact: Ryan Maynard
Phone: 650.624.1284
Email: invrel@rigel.com

SOURCE Rigel Pharmaceuticals, Inc.

Website: http://www.rigel.com